Related Experiment Video
Updated: Jul 5, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma
Nozomi Niitsu1, Masataka Okamoto, Hirokazu Nakamine
1Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan. nniitsu@saitama-med.ac.jp
Abstract:
We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.